{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:35:42Z","timestamp":1789734942309,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic lymphocytic leukemia is a disease of the elderly, and despite major advances in treatment, remains incurable. The Cancer Registry of Norway has registered data on patients with chronic lymphocytic leukemia since 1953. We aimed to analyze trends in incidence and survival of chronic lymphocytic leukemia in Norway. We identified 7664 patients reported with chronic lymphocytic leukemia to the registry between 1953 and 2012. We gathered information on sex, age at diagnosis, date of death and basis for diagnosis. The age\u2010standardized incidence increased from 0.6\/100.000 person\u2010years in 1953 to 3.1\/100,000 person\u2010years in 2012. We found a significant decrease in median age between 1993\u20132002 and 2003\u20132012 (75 vs. 72\u00a0years, 95%\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    : 2.52\u20133.98,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00.001). Men were diagnosed at a significantly younger age than women. Immunophenotyping has become the most important diagnostic method after 2002. Median observed survival increased from 3\u00a0years in 1952\u20131963 to 8.5\u00a0years in 2003\u20132012. Five\u2010 and 10\u2010year age\u2010standardized net survival increased throughout the whole period across age groups and reached 79% and 57%, respectively. Median observed survival was significantly shorter in men than in women in 1993\u20132002 (4.9 vs. 6.1\u00a0years,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00.001). The gap between survival rates for men and women was diminishing in 2003\u20132012 in patients younger than 60\u00a0years while it remained considerable in older patients. Despite an aging Norwegian population, chronic lymphocytic leukemia (\n                    <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>\n                    ) patients become younger at diagnosis. A fourfold increase in incidence, a prolonged survival, and major changes in diagnostic methods in Norway were observed.\n                  <\/jats:p>","DOI":"10.1002\/cam4.849","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:11:16Z","timestamp":1478304676000},"page":"3588-3595","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953\u20132012: a systematic analysis of population\u2010based data"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-4404","authenticated-orcid":false,"given":"Andrea","family":"Lenartova","sequence":"first","affiliation":[{"name":"Department of Haematology Oslo University Hospital  P.O.Box 4950 Nydalen Oslo 0424 Norway"},{"name":"The Institute of Clinical Medicine Faculty of Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom B\u00f8rge","family":"Johannesen","sequence":"additional","affiliation":[{"name":"The Cancer Registry of Norway  P.O. Box 5313 Majorstuen Oslo 0304 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Erland","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[{"name":"Department of Haematology Oslo University Hospital  P.O.Box 4950 Nydalen Oslo 0424 Norway"},{"name":"The Institute of Clinical Medicine Faculty of Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.07.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-129379"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.007849"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9417-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.06.013"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1325::AID-CNCR1454>3.0.CO;2-E"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547737"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_2_7_11_1","unstructured":"Goede V. et\u00a0al.2014.Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions in New England Journal of Medicine. Massachusetts Medical Society."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.037"},{"key":"e_1_2_7_15_1","volume-title":"International Statistical Classification of Diseases, Injuries and causes of Death","author":"WHO","year":"1948"},{"key":"e_1_2_7_16_1","unstructured":"WHO.2002.International Classification of Diseases for Oncology."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591577206500119"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0057-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2011.01640.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.07.002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400679"},{"key":"e_1_2_7_23_1","first-page":"233","article-title":"Kronisk lymfatisk leukemi. Immunofenotyping som hjelpemiddel for riktig diagnose","volume":"118","author":"Ly B.","year":"1998","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28690"},{"key":"e_1_2_7_26_1","first-page":"1","article-title":"Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the International Workshop on CLL guidelines","volume":"2014","author":"Molica S.","year":"2008","journal-title":"Expert. Rev. Hematol."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214346"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27830"},{"key":"e_1_2_7_30_1","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer F.","year":"1961","journal-title":"Natl. Cancer Inst. Monogr."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.849","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:47:26Z","timestamp":1696589246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1002\/cam4.849"],"URL":"https:\/\/doi.org\/10.1002\/cam4.849","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]},"assertion":[{"value":"2016-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}